1. CHARM Program: 3 Component trials comparing candesartan with placebo

2. CHARM Program: Baseline characteristics

3. CHARM Program: Baseline medications

4. CHARM-Overall: CV death and non-CV death

5. CHARM Program: Reduction in mortality and morbidity

6. CHARM Program: Reduction in CHF hospitalization

7. CHARM-Preserved: Hospital admissions for CHF

8. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis

9. CHARM-Overall: Effects of candesartan on CV death or HF hospitalization—Subgroup analysis (cont’d)

10. CHARM-Added: Effect of combined ACE inhibitor/  -blocker/AT1-receptor blocker

11. CHARM-Overall: Drug discontinuations for adverse events

12. CHARM: Clinical implications

13. CHARM-Overall: Reduction in new-onset diabetes

14. CHARM: Impact of treatment

15. HF with preserved LV systolic function in the elderly: Impact on survival

16. CHARM-Preserved: CV death or CHF hospitalization

17. CHARM-Preserved: Primary and secondary outcomes

18. CHARM-Preserved: Clinical implications

19. VALIANT: Design

20. VALIANT: Concomitant medications

21. VALIANT: Treatments show similar effect on outcome

22. VALIANT: Clinical implications

23. VALIANT: Effect of treatment on mortality—Subgroup analysis

24. RESOLVD: Comparative impact of ACE inhibitor, ARB, and  -blocker alone or combined on LVEF

25. Differences in dosing among ARB trials

26. Survival studies of  -blockade in HF

27.  -Blockers improve survival in diabetic patients with HF: A meta-analysis

28. MERIT-HF:  -Blockade improves survival in CHF

29. MERIT-HF:  -Blockade improves survival in post-MI patients with HF

30. MERIT-HF: Subgroup analysis in post-MI patients with HF (LVEF <25%)

31. SOLVD: Heart rate predicts progression of asymptomatic LV dysfunction

32. MERIT-HF: Effect of  -blockade on heart rate

33. MERIT-HF:  -Blockade decreases mortality and hospitalization independent of resting heart rate

34. CHRISTMAS: Design

35. CHRISTMAS: Trial profile

36. CHRISTMAS: Change in LVEF according to number of segments affected by myocardial hibernation

37. COMET: Trial profile

38. COMET: All-cause mortality

39. COMET: Heart rate at each visit

40. COMET: Blood pressure

41.  -Blocker HF trials: Mortality results

42. Mortality rates in perspective CIBIS-II, MERIT-HF, COMET

43. Immediate-release vs sustained release metoprolol: Significant pharmacokinetic differences

44. COMET: Clinical implications

45. Comparison of  -blocker effects in major HF trials

46. Not all  -blockers are the same